We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cirrhosis
MedXY News
EnglishTag

cirrhosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis: A Clinical Review
CardiologycirrhosisPortal Hypertension

Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis: A Clinical Review

By MedXY|Aug 27, 2026

Carvedilol demonstrates superior effectiveness over nadolol and propranolol in reducing portal hypertension and preventing cirrhosis decompensation events, with emerging evidence supporting its preferential use in both compensated and decom

Optimizing Diabetes Management in Cirrhosis: A Practical Clinical Guide
Diabetes & Endocrinologycirrhosisdiabetes

Optimizing Diabetes Management in Cirrhosis: A Practical Clinical Guide

By MedXY|Aug 18, 2026

Cirrhosis entwined with diabetes presents unique clinical challenges. This article offers a pragmatic framework for diagnosis, tailored therapies, and multidisciplinary care to enhance outcomes across liver disease stages.

Rapid Skeletal Muscle Loss in Cirrhosis: Predictors, Outcomes, and Implications for Clinical Management
GastroenterologycirrhosisSarcopenia

Rapid Skeletal Muscle Loss in Cirrhosis: Predictors, Outcomes, and Implications for Clinical Management

By MedXY|Aug 4, 2026

Rapid skeletal muscle loss occurs in a significant subset of cirrhosis patients and independently predicts waitlist mortality, highlighting sarcopenia as a critical therapeutic target in liver disease management.

New A-TANGO Organ Failure Score Refines ACLF Diagnosis and Risk Stratification in Global Cohorts
Critical Carecirrhosisprognosis

New A-TANGO Organ Failure Score Refines ACLF Diagnosis and Risk Stratification in Global Cohorts

By MedXY|Jul 26, 2026

A new organ failure score, A-TANGO, improves ACLF diagnosis and risk stratification compared to standard CLIF-C criteria, validated in large international cohorts.

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients
Clinical Updatesalpha-fetoproteincancer biomarkers

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients

By MedXY|Jul 9, 2026

Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation
Gastroenterologychronic hepatitis Bcirrhosis

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation

By MedXY|Jun 10, 2026

In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base
Clinical Updatescirrhosisend-stage liver disease

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

By MedXY|Jun 9, 2026

A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models

Chronic Kidney Disease Worsens Short-Term Outcomes in Hospitalized Patients With Cirrhosis Across a Global Cohort
Gastroenterologyacute kidney injurychronic kidney disease

Chronic Kidney Disease Worsens Short-Term Outcomes in Hospitalized Patients With Cirrhosis Across a Global Cohort

By MedXY|Jun 7, 2026

In a large international prospective cohort of hospitalized patients with cirrhosis, chronic kidney disease was common, clustered with metabolic risk, and strongly associated with acute kidney injury, more decompensation, and higher in-hosp

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis
Clinical UpdatesBelapectincirrhosis

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis

By MedXY|Jun 1, 2026

This review synthesizes clinical evidence for Belapectin, a Galectin-3 inhibitor, focusing on its ability to prevent esophageal varices in patients with MASH cirrhosis and portal hypertension as demonstrated in the NAVIGATE trial.

Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results
Gastroenterologyabbreviated MRIcirrhosis

Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results

By MedXY|May 13, 2026

A prospective trial found that non-contrast abbreviated MRI detected hepatocellular carcinoma in cirrhotic patients far better than ultrasound, with most MRI-detected tumors found at an early, potentially curable stage.

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models
Gastroenterologycirrhosishepatocellular carcinoma

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models

By MedXY|Apr 23, 2026

The Translational Liver Cancer Consortium proposes a structured framework for developing and validating risk models to optimize HCC surveillance, addressing gaps in current clinical guidelines.

Stratifying Risk in Incidentally Detected Splenomegaly: Quantitative Thresholds for Hematologic and Hepatic Surveillance
Clinical Updatescirrhosisliver cancer

Stratifying Risk in Incidentally Detected Splenomegaly: Quantitative Thresholds for Hematologic and Hepatic Surveillance

By MedXY|Mar 22, 2026

This review synthesizes large-scale cohort data defining specific spleen length and volume thresholds that significantly increase the 5-year absolute risk of hematologic cancers and chronic liver disease.

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit
Gastroenterologyantibiotic prophylaxisbayesian meta-analysis

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

By MedXY|Nov 25, 2025

A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study l

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context
Clinical UpdatesALDcirrhosis

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

By MedXY|Nov 24, 2025

This review synthesizes evidence on rising cirrhosis incidence in Sweden, highlighting marked socioeconomic disparities particularly in ALD- and MASLD-related cirrhosis, with broader implications across high-income countries for targeted pr

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
Gastroenterologyanticoagulationcirrhosis

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY|Oct 28, 2025

The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
Gastroenterologyanticoagulationcirrhosis

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY|Oct 28, 2025

The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding

Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications
Gastroenterologycirrhosisprognosis

Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications

By MedXY|Oct 28, 2025

Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may g

RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting
Critical CareACLFbiomarker

RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting

By MedXY|Oct 28, 2025

RIPK3-associated necroptosis critically drives organ failure and mortality in acute decompensation and ACLF, with its plasma levels robustly predicting outcomes and improving prognostic models to guide personalized therapies.

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis
Gastroenterologycirrhosisliver stiffness measurement

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis

By MedXY|Oct 28, 2025

This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in bio

Early Portopulmonary Hypertension in Cirrhosis: A Prognostic Marker of Increased Mortality
Cardiologycirrhosismortality prediction

Early Portopulmonary Hypertension in Cirrhosis: A Prognostic Marker of Increased Mortality

By MedXY|Oct 27, 2025

Early-stage portopulmonary hypertension, defined by revised 2022 ESC/ERS criteria, independently predicts mortality in patients with cirrhosis, underscoring the importance of systematic screening and early intervention.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities